Pricing and Reimbursement of Pharmaceuticals in Belgium

被引：0
|
作者：
Lieven Annemans
Ralph Crott
Henri De Clerq
Michel Hyuybrechts
Frank Peys
Hugo Robays
Ingrid Steens
Kathleen Vanschoubroek
Peter Winderickx
机构：
[1] BRI International,
[2] Université Catholique de Louvain,undefined
[3] E.S.S.T.,undefined
[4] Vrije Universiteit Brussel,undefined
[5] Astra Pharmaceuticals Belgium,undefined
[6] Belgian Institute for Health Economics,undefined
[7] University Hospital Gent,undefined
[8] Amgen,undefined
[9] Dworp,undefined
来源：
PharmacoEconomics | 1997年 / 11卷
关键词：
Economic Evaluation; Contingent Valuation; Sickness Fund; Price Setting; Pharmacoeconomic Evaluation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The Belgian healthcare system has a tradition of access and equity at affordable prices. As in other countries, the system becomes pressured by increasing healthcare costs. This paper describes the actual situation in Belgium with special focus on pharmaceutical products and the potential role of pharmacoeconomics in decision making on price and reimbursement.
引用
收藏
页码：203 / 209
页数：6
相关论文
共 50 条
12345